Search by ticker code:
Generic filters

FY20 result: ResMed (ASX:RMD) profit jumps 40%

The ResMed Inc (ASX: RMD) profit jumped 40% in its FY20 result due to high ventilator and ventilation mask demand. The ResMed share price is expected to open lower.

ResMed is one of the businesses that manufactures the breathing apparatus used by hospitals to help patients who are suffering seriously from COVID-19.

ResMed’s FY20 profit numbers

ResMed announced today that in the fourth quarter of FY20 its revenue rose by 9% to US$770.3 million. Its non-GAAP profit margin improved by 60 basis points (0.60%) to 59.9%. A higher profit margin means it’s more profitable with its revenue, more revenue is turned into profit.

FY20 fourth quarter net operating profit increased by 84% to US$223.2 million. Non-GAAP net operating profit increased 24% to US$243.4 million.

This final quarter contributed to a strong 2020 result. Revenue rose by 13% to US$2.96 billion. The gross margin improved by 80 basis points (0.80%) to 59.8%.

Net operating profit increased by 40% to US$809.7 million and non-GAAP income from operations rose 24% to US$890.9 million.

What caused the large rise in profit?

The main area of growth was revenue in Europe, Asia and other markets in the fourth quarter where revenue increased 22% on a constant currency basis mainly due demand for ventilators due to COVID-19. Software as a service (SaaS) revenue rose 7% in the fourth quarter. Costs reducing by 4% also helped.

Management comments

ResMed CEO Mick Farrell said: “Our fourth quarter results reflect the strength and resiliency of our business in today’s uncertain environment.

We continued to support the COVID-19 pandemic response through increased manufacturing of our ventilators, including bilevels and ventilation mask systems while also supporting our customers with digital health solutions and other innovative tools to enable remote care for patients. Looking ahead, we are confident in our ability to navigate through the ongoing challenging clinical and economic environment to deliver for all our stakeholders. Sleep labs and physician practices are reopening across many geographies, and we’re seeing accelerated adoption of digital health solutions which supports our long-term strategy.”

ResMed dividend

The ResMed board decided to declare a quarterly cash dividend of US$0.39 per share.


ResMed has had a very strong year – its share price is up 27% since 1 January 2020. I think there could be a danger of some investors expecting that the current level of ventilator demand will continue indefinitely. Unless COVID-19 is here forever, I think hospital needs will taper off during 2021.

I’m not sure what the right price to pay for ResMed is due to that high level of demand uncertain, though its SaaS revenue growth will help on the other side of COVID-19. I’d call it a cautious buy today, but there are other ASX growth shares I’d buy first such as Bubs (ASX: BUB) which are much smaller with more long term growth potential.

[ls_content_block id=”14948″ para=”paragraphs”]

FREE & NEW: Our Complete Passive Income Strategy

With interest rates UP, now is one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% -- or more -- in dividend passive income from the best shares, LICs, or ETFs... it's like free money credited to your bank account.

So how do the best investors do it?

Whether you have $2,000 or $2,000,000, our Chief Investment Analyst Owen Rask has just released his brand new ASX Passive Income Report. Featuring the best dividend ETFs, LICs, funds and shares, this report cannot be missed by anyone wanting passive income in 2022 and 2023.

You can INSTANTLY access Owen's report -- or get it emailed to you -- for FREE by CLICKING HERE NOW or the button below.

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.